Outlook Therapeutics, Inc. Common Stock
OTLKOutlook Therapeutics, Inc. (OTLK) is a biopharmaceutical company focused on developing and commercializing ophthalmic biologics. The company's lead product candidate, ONS-5010, is an anti-VEGF monoclonal antibody designed for the treatment of eye diseases such as wet age-related macular degeneration, diabetic retinopathy, and other retinal vascular diseases. Outlook aims to provide accessible and effective treatments for preserving and improving vision.
Company News
Outlook Therapeutics announced a $5.0 million registered direct offering of 8.5 million shares at $0.5855 per share to its largest stockholder GMS Ventures and Investments. The company also agreed to amend outstanding warrants held by GMS Ventures, reducing the exercise price from $1.78 to $0.5855 per share. Proceeds will be used for working capi...
Outlook Therapeutics (NASDAQ: OTLK) announced a best-efforts public offering of common stock and accompanying warrants to raise capital for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is subject to market conditions with no assurance of completion timing or terms.
U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4%...
The retinal and fundus camera market is experiencing growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). The integration of artificial intelligence (AI) into fundus cameras presents a significant opportunity for market growth, with AI algorithms demonstrating high acc...
Outlook Therapeutics, a biopharmaceutical company, announced the pricing of a $13.0 million public offering of common stock and accompanying warrants. The company plans to use the net proceeds for working capital and general corporate purposes.
